The 7th International Conference on Prehypertension, Hypertension, Metabolic Disorders and Cardiovascular Disease is organized by Paragon Group and will be held from Apr 02 - 05, 2020 at Vilnius, Lithuania.
Who Should Attend:
The Conference aims at experts from the fields of :
• Cardio Metabolic Syndrome
• Clinical Trials
• Family Medicine
• Heart Failure
• Imaging – Innovative & Routine Methods
• Internal Medicine
• Physical Activity Professionals
• Vascular disease
The definition of borderline levels of blood pressure, plasma glucose and plasma lipids changed during the last decades. When clustering of these appears, it is not easy to decide about treatment- when it should be initiated and how will be the best way to protect the patient from complications and to prevent development of cardiovascular disease. In principle, therapeutic decisions were made by estimating the patient’s cardiovascular risk. The higher the risk the earlier treatment should be initiated.
It has been shown that clustering of the components of the Cardiometabolic syndrome magnifies significantly the rate of progression of both atherosclerosis and arteriosclerosis, leading to overt damage in the heart, brain, kidneys and other organs.
Multiple factors affect the rate of progression of damage, among them- genetic factors, lifestyle, stress, smoking, alcohol intake and others. Interventions like change in life habits and medical treatment to correct all components of the Cardiometabolic syndrome – lowering blood pressure, plasma cholesterol, plasma glucose, treatment of obesity and cessation of smoking and of alcohol intake should be performed in each patient.
Organ specific changes appear and lead to morbidity and mortality. Damage to the heart can include coronary artery disease, cardiac hypertrophy, diastolic dysfunction and leads to IHD, myocardial infarction, heart failure and death. In the brain changes in the large arteries like the carotid artery, supplying blood to the brain and the small arteries, can lead to cerebrovascular ischemia and infarction, which can be embolic or ischemic. The damage can lead to lacunar infarcts, ischemic or hemorrhagic stroke, causing disability and death.
In approaching this wide world problem, we should act to prevent the damage and when already present to stop its progression and even to induce damage regression.
The research in the field needs new diagnostic methods in order to enable early diagnosis before symptom development and new therapeutic approaches, medical and instrumental.
Understanding of yet unknown pathophysiologic aspects of disease development are also needed.
The purpose of our meeting is to discuss in depth new mechanisms of cardiovascular damage development, novel methods of diagnosis and new therapeutic approaches.
• Approach to the Elderly with Borderline Metabolic Conditions
• Arterial Properties, Central Blood Pressure and Augmentation Index in the Continuum of Prehypertension and • Hypertension
• Arterial Properties, Evaluation and Treatment in Borderline Conditions
• Assessment of Global Cardiovascular Risk Factors in Borderline Conditions
• Benefits of Achieving Optimal Risk Factors Level – When, How and with What?
• Biomarkers of Borderline Conditions and Preclinical Disease
• Borderline Cardiovascular Risk Factors - Morbidity and Mortality
• Children and Adolescents and Cardiovascular Risk Factors- Diagnosis, Estimation of Risk and Treatment
• Complications of Prehypertension, Hypertension and Cardiometabolic Syndrome: the Heart, the Brain, the • Kidney and the Extremities
• Cumulative Effects of Multiple Borderline Cardiometabolic Risk Factors
• Diabetes, Prevention, Mechanisms and Treatment of end Organ Damage
• Humoral Factors in Prehypertension and Cardiometabolic Syndrome
• Hypertension, Mechanisms and Therapeutic Approach
• Management of Dyslipidemia, Mechanisms and Novel Therapeutic Regimens
• Metabolic Syndrome and Borderline Metabolic Conditions
• Natural History of Prehypertension, Hypertension and End Organ Damage
• Obesity, Mechanisms and Therapy
• Prediabetes – Mechanism, Diagnosis, and Management
• Prehypertension and Metabolic Syndrome in Different Populations – Epidemiology
• Prehypertension, Cause and Results
• Prehypertension, Prediabetes and Dyslipidemia – Estimation of Risk and Therapeutic Approach
• Prehypertension – Progression of Risk and Diagnosis of Disease
• Prehypertension- Mechanism, Diagnosis and Management
• Prevention and Regression of End Organ Damage in Prehypertension
• The Heart, the Brain and the Kidney in Prehypertension and Cardiometabolic Syndrome
• Total Cardiovascular Risk Evaluation and Management
Additional details will be posted as soon as information is available.
|Contact No. :||+41 22 5330 948
January 16, 2020
|Registration Type||Last Date||Price|
|Participant - Conference Fee||30 Mar,2020||EUR 700.00|
|Nurse/Para Health Provider- Conference Fee||30 Mar,2020||EUR 600.00|
|Participant from the Baltic countries: Lithuania, Latvia, Estonia Fee||02 Apr,2020||EUR 250.00|
|Student/Resident- Conference Fee||30 Mar,2020||EUR 500.00|
|Accompanying Person Fee||02 Apr,2020||EUR 45.00|
|Registration Type||End Date||Price|
|Participant - Early Fee||19 Dec,2019||EUR 550.00|
|Participant - Regular Fee||03 Feb,2020||EUR 600.00|
|Nurse/Para Health Provider- Early Fee||19 Dec,2019||EUR 450.00|
|Nurse/Para Health Provider- Regular Fee||03 Feb,2020||EUR 500.00|
|Student/Resident- Early Fee||19 Dec,2019||EUR 400.00|
|Student/Resident- Regular Fee||03 Feb,2020||EUR 445.00|